ABSTRACT 26
Individuals with complex disorders typically have a heritable burden of common variation 27 that can be expressed as a polygenic risk score (PRS). While PRS has some predictive utility, 28 it lacks the molecular specificity to be directly informative for clinical interventions. We 29 therefore sought to develop a framework to quantify an individual's common variant 30 enrichment in clinically actionable systems responsive to existing drugs. This was achieved 31 with a metric designated the pharmagenic enrichment score (PES), which we demonstrate for 32 individual SNP profiles in a cohort of cases with schizophrenia. A large proportion of these 33 had elevated PES in one or more of eight clinically actionable gene-sets enriched with 34 schizophrenia associated common variation. Notable candidates targeting these pathways 35 included vitamins, insulin modulating agents, and protein kinase inhibitors with putative 36 neuroprotective properties. Interestingly, elevated PES was also observed in individuals with 37 otherwise low common variant burden. The biological saliency of PES profiles were 38 observed directly through their impact on gene expression in a subset of the cohort with 39 matched transcriptomic data, supporting our assertion that this framework can integrate an A significant burden of disease is caused by complex traits including psychiatric and 52 neurobehavioural disorders, inflammatory and autoimmune disorders, metabolic and 53 cardiovascular disease, and cancer. Until relatively recently it was difficult to identify the 54 heritable components of these traits, however, the emergence of well powered genome-wide 55 association studies (GWAS) using large cohorts assembled by collaborative consortia are 56 revealing important insights into their common variant architecture 1 . While collectively this 57 information has been vital to map genes and pathways that are likely to be etiological factors, 58 the small effect size of each variant, and their heterogeneity in the population make their 59 relevance to individuals with the disorder highly variable, relatively specific, and fairly minor 60 with respect to the total variant burden. They also present as relatively small targets for 61 therapeutic intervention and may not attract the investment needed for pharmaceutical 62 development. We therefore need mechanisms for using this vast amount of diverse genetic 63 information to maximise its utility for therapeutic advances. This requires a personalised 64 approach that can capture variant burden in affected individuals with respect to biological 65 components that align with existing medications, and/or pathways of relevance to key 66 pathophysiological processes, to provide sufficient support for the development of new 67 interventions. 68 69 While approaches that summate the genomic risk burden in individuals, such as polygenic 70 risk scoring (PRS), have demonstrated some predictive utility for complex traits (such as 71 neuropsychiatric disorders 2; 3 , diabetes 4; 5 , cardiovascular disease 6; 7 , and inflammatory 72 disorders 8; 9 ) their composition of heterogeneous risk factors lack the biological salience 73 needed to design a precision treatment strategy. We, however, hypothesized that the 74 biologically supervised enrichment of trait-associated common variants in clinically 75 actionable pathways would provide a means of pharmacologically annotating PRS in 76 individuals. To test this proposal, we devised a statistical framework for scoring polygenic 77 risk (at the multivariable level) in pathways relevant as therapeutic targets for complex traits. 78
This quantitative approach, designated the pharmagenic enrichment score (PES), was 79 developed to provide an indication of an individual's exposure to risk variants that are 80 potentially treatable by existing pharmacological agents, including many that have never 81 been considered or tested previously for the condition/disorder they are experiencing. By 82 focusing on biological pathways with known drug targets, we endeavour to enhance the 83 clinical utility of polygenic risk approaches by providing novel and specific opportunities to 84 identify treatment targets and/or repurpose existing drugs. This application of genome-wide 85 common variant genotyping should have particular relevance for the precision treatment of 86 individuals that are resistant to currently indicated medications. In this study we outlined the 87 PES approach and sought to exemplify its utility in individuals with the complex psychiatric 88 condition, schizophrenia. 89 90 91
MATERIALS AND METHODS 92
Pipeline for the derivation of pharmagenic enrichment scores 93
The methodology developed for constructing pharmagenic enrichment scores (PES) is 94 outlined in a schematic presented in Supplementary Figure 1 . We exploit the results of gene-95 set association analysis to aggregate variants from GWAS into gene-sets which may be 96 candidates for pharmacological intervention. These gene-sets were high quality canonical and 97 hallmark pathways sourced from the molecular signatures database (MSigDB) 10 . Pathways 98 were designated as clinically relevant if they contained at least one gene annotated to interact 99 with an approved pharmacological agent in the DrugCentral database as classified by the 100 Target Central Resource Database (TCRD, genes annotated as TClin) 11 . 101 102 Firstly, this process tests the combined effect of variants at the gene level. We utilised an 103 omnibus P value test to achieve this, whereby a linear combination of variant-wise P values 104 in a gene is compared to a null distribution to derive a combined P value for that gene. This 105 was performed using the MAGMA package to account for linkage disequilibrium between 106 variants in the approximation of the null # distribution 12 . We mapped SNPs to protein 107 coding genes (hg19, NCBI) with the genic boundaries encompassing 5kb upstream and 1.5 108 kb downstream to capture variation in regulatory regions. Genes within the major 109 histocompatibility complex (MHC) on chromosome 6 were excluded from this study due to 110 the complexity of haplotypes in that region. Traditionally, the full breadth of variants 111 available in the summary statistics are utilised in these models. This, however, may miss 112 important aspects of the biological interpretation of the genomic signal. PRS derived from 113 large GWAS cohorts are tested at different P value thresholds (PT) to exploit a model which 114 explains the most variance between the case and control groups (in a dichotomous construct). 115
For instance, a PT < 0.05 means that only P values in the GWAS with a stronger association 116 (P value) than this threshold are included. A range of PT have been suggested to be optimal 117 for PRS in several disorders depending on their genomic architecture 2; 7; 13 . Aggregating the 118 combined effects of variants in genes at different PT may therefore capture the biological 119 complexity of the signal at varying degrees of polygenicity. 120 To identify clinically actionable gene-sets and construct PES, we processed the 2014 135 psychiatric genomics consortium GWAS for the complex neuropsychiatric disorder 136 schizophrenia with the pipeline described above 3 . Variants were selected based on their 137 significance (P value) for inclusion in the at four different thresholds -all SNPs, P < 0.5, P < 138 0.05, and P < 0.005. Geneset association was conducted on 1012 MSigDB pathways with at 139 least one druggable (TClin) gene. To capture a wide variety of pathways for a complex 140 phenotype like schizophrenia, we used a nominal significance threshold of P < 0.001 to select 141 candidate pathways for PES. 142
143
We annotated each of these candidate pathways for their drug interactions, tissue specificity, 144 and phenotypic associations. Using WebGestalt, drugs which target a statistically significant 145 number of genes in the PES gene-sets were identified after the application of multiple testing 146 correction (FDR < 0.05) 14 . A minimum overlap of at least three targets overlapping the 147 geneset for each pharmaceutical agent was also implemented. Drugs were also mapped to 148 gene-sets using DGidb v3.02, with the top FDA approved drug per pathway was selected 149 based on the DGidb score of interaction confidence between a TClin gene and drug 15 . Further, 150 the tissue specificity of expression for all genes from the eight pathways was investigated 151 using GENE2FUNC application of FUMA 16 . Transcript expression in each of the 53 tissue 152 types in the GTEx v7 dataset for the input pathway genes was tested for upregulation, 153 downregulation and two-sided differential expression in comparison to the entire protein-154 coding genome. Enrichment of input genes for associated traits in GWAS catalogues was 155 also tested in the FUMA framework. using the 1000 genomes phase 3 European reference panel, has been outlined in detail for this 167 cohort previously 18 . High quality autosomal sites with low missigness (< 2%) and an 168 imputation score greater than 0.8 (R 2 > 0.8) were retained for analysis in this study. After the 169 removal of individuals in the post-genotyping quality control, 425 schizophrenia cases and 170 251 controls were analysed in this study; cases were 67% male, whilst males comprised 44% 171 of the control cohort (Supplementary Table 5 ). The use of these data was approved by the 172
University of Newcastle Human Ethics Research Committee (HREC). 173
PES is calculated from SNPs mapped to genes which form the candidate pharmacologically 174 actionable geneset. This comprises the following model (1) which sums the statistical effect 175 size of each variant in the geneset multiplied the allele count (dosage) for said variant-for 176 individual , let & ' denote the statistical effect size from the GWAS for each variant in the 177 candidate gene-set, multiplied by the dosage ( ) of in . 178
This was calculated for the individuals using the PRSice2 package 19 . For each PES, the PT 180 used to derive the score was selected based on which PT the corresponding geneset was 181 derived from the GWAS, when a geneset was associated at multiple PT, the most significant 182 was chosen. A genome-wide PRS (PRSTotal) was also constructed for this cohort, with the PT 183 which explained the most variance between cases and controls selected using Nagelkerke's 184 R 2 . Association for each of the scores with cases was conducted using binomial logistic 185 regression, adjusted for sex and the first three principal components using R 3.4.4. P values 186 were derived using the Wald test with and without the total PRS score at the optimum 187 threshold as a covariate in the model. 188
189
Each PES was ranked for individuals within the ASRB cohort, with three metrics used to 190 define a person with an 'elevated PES' score: the top percentile, decile, and quartile of the 191 study population. The number of pathways which pass these thresholds were totalled for each 192 individual and the association between these totals and schizophrenia assessed using the same 193 model as for univariate PRS as described above. To investigate the relationship between Using the complete summary statistics, we identified eight clinically actionable gene-sets (at 232 the different PT) containing known drug targets ( Table 1 ). The most significantly associated 233 of these was the HIF-2 pathway (P = 3.12 x 10 -5 , b = 0.435, SE = 0.109, PT < 0.005), which 234 is comprised of genes in the hypoxia inducible factor 2 (HIF-2) alpha transcription factor 235 network. One carbon pool by folate was the second most significant pathway with a putative 236 The genes which constitute these eight pathways had upregulated expression in the brain 244 relative to the rest of the protein coding genome, with the anterior cingulate cortex the most 245 highly enriched region after multiple testing correction, PAdj = 6.45 x 10 -13 . Conversely, they 246 were downregulated (PAdj < 0.05) in several peripheral tissues including the stomach and skin 247 ( Supplementary Fig. 2) . These genes were also overrepresented in the GWAS catalogue for 248 traits relevant to psychiatry including schizophrenia, post-traumatic stress disorder, nicotine 249 dependence and cognitive performance (PAdj < 0.05, Supplementary Table 1 ). 250 
Individual profiling of pharmagenic enrichment scores in a schizophrenia cohort 295
We profiled PES in a cohort of schizophrenia patients and screened healthy controls 17 and 296 identified members of the cohort with relatively high PES in clinically actionable gene-sets. 297
Firstly, we examined individuals in the top percentile of the ASRB cohort for each PES, to 298 explore the phenotypic characteristics of an elevated risk score with high confidence. There 299 were 55 individuals with a top percentile PES, as one schizophrenia case had elevated PES in 300 both the One Carbon Pool by Folate and the GABA synthesis, release, reuptake and 301 degradation pathways. From this subset, the majority were schizophrenia patients (N=38), 302 however, there was no significant association between top percentile status and diagnosis (z = 303 0.975, P = 0.33). We investigated clinical characteristics obtained for ASRB participants to 304 prioritise top percentile PES carriers who may benefit most from a personalised treatment 305 regime. Three variables were selected as a proxy of a more clinically challenging 306 presentation of the disorder: clozapine prescription (as a surrogate for treatment resistance), a 307 global assessment of functioning (GAF) score < 50, and an adolescent onset of the disorder 308 before the age of 18 33; 34 . Interestingly, of the 38 schizophrenia cases with an elevated PES, 309 71% of this subset meet at least one of these criteria (N =27): clozapine prescription (N = 9), 310 GAF < 50 (N = 12), onset age < 18 (N = 9). 311
312
In addition, two less stringent partitions of elevated PES were implemented, specifically, a 313 decile and quartile cut-off for PES in the entire cohort was used to triage patients at elevated 314 risk of dysfunction in that pathway. The highest number of PES in the top decile or quartile 315 respectively for an individual was six ( Supplementary Fig. 3 ). An increasing number of PES We sought to define the relationship between PRSTotal and PES in further detail. Pairwise 371 correlation between each of the scores demonstrated no significant univariate relationship 372 between any PES or with PRSTotal (Fig. 1a ). In addition, top percentile PES individuals were 373 not enriched with PRSTotal in comparison to the rest of the cohort: z = 0.819, P = 0.413 ( Fig.  374   1d ). This presented a clinically significant subset of schizophrenia cases with a less polygenic 375 phenotype, that is, low PRSTotal relative to the schizophrenia cohort but high heritable risk in 376 one or more pathways. Analysis of the bottom quartile of PRSTotal in the ASRB schizophrenia 377 cohort revealed cases (N=10) with top percentile PES but depleted PRSTotal. The pathways 378 encompassed in these individuals were: Acetylcholine (N=3), Hedgehog signalling (N=2), 379
CRMPs in Sema3A (N=2), GABA (N=1), HIF-2 (N=1) and Insulin secretion (N=1). This 380 information may be of great clinical value as these cases have less marked common variant 381 burden genome-wide, but localised risk in a geneset. Furthermore, three of these patients 382 were prescribed clozapine (surrogate for treatment resistance), a further three had low global 383 functioning (GAF < 50), along with two adolescent onset cases -potentially highlighting a 384 heightened need for precision intervention in these individuals. 385
386
To investigate the relationship between low polygenic load and elevated PES, genome wide 387 PRS and the PES category count in the top decile per individual were clustered using finite 388
Gaussian mixture modelling (GMM). The optimal number of clusters was selected based on 389 parametrisation of the covariance matrix utilising the Bayesian Information Criterion (BIC), 390 with the highest BIC value used for selection of the number of clusters ( Fig. 2a ). Four 391 clusters were derived from the data (BIC = 13871.21, VEV: variable volume, equal shape, 392 variable orientation) (Fig. 2b) Each PES profile was tested for association with the peripheral blood expression of genes 434 within their respective pathways for a subset of schizophrenia cases with expression data 435 available ( Fig. 3, Supplementary Table 6 ). After covariation for sex, age, and PRSTotal, the 436 NOS1 PES was associated with downregulated expression of the calcineurin subunit gene 437 PPP3CC (t = -3.08, P = 2.9 x 10 -3 , q = 0.05). This was followed by the regulation of insulin 438 secretion PES, which was associated with decreased expression of the syntaxin gene STX1A 439 (t = -3.5, P = 8.1 x 10 -4 , q = 0.055); and the One carbon pool by folate gene PES, which was 440 associated with downregulation of serine hydroxymethyltransferase 2 (SHMT2; t = -2.94, P = 441 4.5 x 10 -3 , q = 0.072). Excluding these three genes (q < 0.1), there were eleven others with a 442 nominally significant (Raw P < 0.05) relationship with a PES, with all PES profiles except 443 genetic components associated with complex syndromes, for the purpose of delineating 469 clinically meaningful biological systems, will both better target existing treatments and reveal 470 new opportunities for drug repurposing (Fig. 4a ). In this study, we developed a novel method 471 for capturing common variant risk in biological networks with known drug interactions -472 pharmagenic enrichment scores (PES) -to facilitate precision treatment design relevant to 473 individuals with a particular set of risk variants. A distinct advantage of our PES approach is 474 that it can capture latent enrichment of polygenic signal in pathways relevant to 475 pharmaceutical actions, among individuals whose overall trait PRS is low relative to others 476 with a shared phenotype. Even in cases where polygenic burden is high, genome-wide PRS 477 (as a biologically unannotated instrument) does not necessarily provide insight into pathways 478 suitable for pharmacological intervention in individuals. Our approach for selection of 479 putative drug targets exemplified in schizophrenia GWAS has revealed potential targets for 480 drug repurposing with substantial clinical utility. 481 482 Aggregation of common variation from schizophrenia GWAS into biological pathways with 483 known drug interactions revealed a diverse array of systems relevant to eight distinct PES 484 categories. These candidate pathways displayed common variant enrichment at a range of PT, 485 indicative of the degree of polygenicity, ranging from using all SNPs as input, to a 486 significance threshold below 0.005 (PT < 0.005). While two of these pathways included 487
GABAergic and cholinergic neurotransmission, both of which are intuitive candidates that 488 have been extensively implicated in schizophrenia with associated drugs already in common 489 practice for neuropsychiatric disorders 39; 40 , many others were more surprising. The most 490 significantly associated gene-set pertained to the HIF-2 transcription factor network, an 491 important mediator in response to decreases in available cellular oxygen. This has clear 492 significance for biological mechanisms involved in psychiatric disorders, for example in 493 dopaminergic signalling 41 . Enrichment of ascorbic acid (vitamin C) targets in this pathway is 494 notable from a therapeutic perspective because of its antioxidant capabilities, along with 495 preliminary evidence for its efficacy as an adjuvant in the treatment of the disorder 29; 30 . The 496 interaction between HIF-2 signalling and NOS1 signalling, another candidate pathway with 497 pharmagenic enrichment in schizophrenia, is supported by previous evidence of redox 498 dysfunction in the disorder 42; 43 . The activity of glutamate receptors in the NOS1 system 499 suggests that psycholeptics and psychoanaleptics are likely to modulate this pathway. We 500 also observed common variant enrichment in two developmental pathways that can be 501 pharmacologically modulated: CRMPs in semaphorin 3a signalling and Hedgehog signalling. 502
The former is able to interact with the tyrosine kinase inhibitor Dasatinib, which is postulated 503 to have neuroprotective properties 44 . Enrichment in these actionable pathways is consistent 504 with longstanding hypotheses of deficits in neurodevelopment contributing to the aetiology of 505 schizophrenia 45 . There is also evidence for aetiological overlap between schizophrenia and 506 diabetes beyond what is attributable to metabolic effects of antipsychotic treatment, which 507 supports our identification of an insulin related pathway as a candidate PES [46] [47] [48] . 508
509
The breadth of drugs which target these pathways used to construct PES suggests that 510 individual level treatment formulation can become highly specific depending on which 511 systems genomic risk is localised. This would include the stratification of individuals for 512
precision treatment with compounds previously tested on undifferentiated schizophrenia 513 cohorts, including, N-acetylcysteine, vitamin C, Atomoxiene, and Varenicline which were 514 identified using PES in this study 24-26; 29 . Repurposing drugs for individuals informed by 515 their genetic liability may assist in the reduction of response heterogeneity, which hinders the 516 implementation of novel treatments in very complex phenotypes like schizophrenia. We 517 suggest that the individuals with PES in the top percentile of any pathway, particularly those 518 with low genome wide PRS, present as the most tractable candidates for this approach; 519 whereas the clinical significance of particular sets of common variant burden would be 520 missed by an unannotated genome wide association indexed by total PRS alone. 521
522
In order to better understand how PES profiles could be leveraged for treatment, the effect of 523 sequence variation which comprises the PES needs to be investigated. We outlined an 524 example of this approach in this study by testing the effect of PES on the expression of genes 525 which comprise each pathway in schizophrenia. Several associations between PES and 526 mRNA expression were observed after correcting for the number of genes within the tested 527 set. These effects may arise due to direct cis-acting loci within the PES and/or the 528 downstream biologic effects of variation which effect genes with interrelated functionality. 529
This was exemplified by the Regulation of insulin secretion PES, which was negatively 530 correlated with STX1A expression, a syntaxin postulated to play a role in insulin homeostasis. 531
Interestingly, STX1A has been shown to be positively correlated with glucose stimulated 532 insulin secretion, suggesting downregulation conferred by the PES may have an important 533 effect through this biological pathway 49; 50 . Similarly, downregulation of the calcineurin 534 subunit gene PPP3CC was associated with the NOS1 pathway PES. Previous research 535 suggests there is a bidirectional relationship between nitric oxide signalling and calcineurin, 536
where the calcineurin subunit is both regulated by redox products and able to induce nitric 537 oxide synthesis 51; 52 . Several other genes had suggestive association with PES profiles which 538 may be established with a larger cohort. We suspect that this approach to validation would be 539 particularly informative for schizophrenia in genotyped expression cohorts from brain tissue. 540 541 While we expect that in most circumstances the aggregate of variation constituting high PES 542
represent pathology of the target pathways, a current limitation of this methodology is that it 543 does not integrate the direction of effect. While this may be possible as more functional 544 annotations become available, this would present an immensely complex paradigm to predict 545 in silico due to the vast array of factors which influence the penetrance of genomic risk. We 546 believe that an analysis of the effect of PES profiles on gene expression in larger cohorts will 547 be an important future direction of this work. The impact of candidate molecules could also 548 be modelled in patient derived cell lines to, firstly, establish the extent of dysregulation 549 conferred by elevated PES and, secondly, investigate the interaction with the compounds 550 implicated. The current analysis also used very stringent criteria for drug pathway gene 551 inclusion and there are likely to be many more genes and pathways that may be implicated in 552 future ontologies and other investigator curated gene-sets. In a recent example of this we 553 observed an enrichment of retinoid gene variation in schizophrenia 18 . 554 555 New GWAS summary statistics are emerging daily on ever larger samples and these too will 556 further enrich the substrate for PES determination and increase its clinical utility. Despite the 557 aforementioned challenges, we believe that this methodology provides a useful framework to 558 better utilise the breadth of available GWAS data for personalised treatment formulations. 559
Particularly, as there remains a largely unmet need to translate polygenic risk for complex 560 disorders into tractable treatment outcomes for affected individuals. Whilst we have 561 demonstrated here the potential utility in schizophrenia, there is clearly scope to adapt this 562 analytical approach to other complex disorders with summary statistics from well-powered 563 GWAS. This methodology may also be applicable to prophylactic intervention for 564 individuals at high risk for a complex phenotype (Fig. 4b ). This could be implemented 565 conservatively with lifestyle or dietary measures implicated by clusters of enrichment 566 captured within the PES framework. For example, in schizophrenia we identified multiple 567 actionable pathways quantified by PES that are modulated by vitamins, which represent a 568 relatively uncomplicated intervention for individuals at high genetic risk for this disorder. Supplementary Table 1 . Overrepresentation of genes within candidate PES pathways in the 599 GWAS catalogue traits with relevance to psychiatry after multiple testing correction. 600 Supplementary Table 2 . Highest confidence drug interaction between of a member of each 601 pathway enriched with common polygenic risk for schizophrenia. 602
